middle.news
Alterity Therapeutics Nears ATH434 Trial Results Amid Tight Cash Position
7:03pm on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Alterity Therapeutics Nears ATH434 Trial Results Amid Tight Cash Position
7:03pm on Monday 2nd of June, 2025 AEST
Key Points
Completion of ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy
Topline results expected by early February 2025
Positive interim data from ATH434-202 trial in advanced MSA suggests disease modification potential
Cash balance of A$4.54 million with quarterly operating outflows of A$5.06 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE